[Effectiveness of prophylactic administration of anti-Rh (D) immunoglobulin, based on immunofluorescent and cytochemical methods of fetal hemoglobin determination].
D000941:Antigens; D004899:Erythroblastosis, Fetal / Q000517:prevention & control*; D005260:Female; D005319:Fetal Hemoglobin / Q000032:analysis*; D005333:Fetus / Q000276:immunology; D005455:Fluorescent Antibody Technique; D006651:Histocytochemistry; D006801:Humans; D007072:Immunoglobulin D / Q000008:administration & dosage*; D007231:Infant, Newborn; D007518:Isoantibodies / Q000032:analysis; D008431:Maternal-Fetal Exchange; D008722:Methods; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System; D013997:Time Factors
D000941:Antigens; D007072:Immunoglobulin D; D007518:Isoantibodies; D012204:Rh-Hr Blood-Group System; D005319:Fetal Hemoglobin
Ocena skuteczności profilaktyznego stosowania immunoglobuliny anty Rh (D) oparta na badaniach immunofluorescencyjnych i cytochemicznym oznaczaniu hemoglobiny płodowej.